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Abstract 
Background: Clinical therapy for metastatic colorectal cancer (CRC) remains limited, especially when the tumor har‑
bors a KRAS mutation. This study aimed to identify prognostic biomarkers in CRC that are accessible for therapeutic 
inhibition.
Methods: Conditioned media from human CRC epithelial cells and myofibroblasts were screened by cytokine arrays 
for tumorigenic factors. The protein and mRNA expressions of these factors were determined by immunohistochem‑
istry and gene microarrays in human CRC tissues. Prognostic biomarkers were determined by correlation of mRNA 
expression to overall survival in stage IV CRC patients. Inhibition of CXCL1 was performed with specific neutralizing 
antibody and lentiviral shRNAs. Malignant growth was assessed by soft agar growth assays and xenograft tumor 
growth in immunocompromised mice.
Results: CXCL1 was highly secreted by KRAS mutant human CRC cells and myofibroblasts in a complementary 
adaptive response to serum deprivation. Elevated CXCL1 level promoted anchorage‑independent growth of murine 
fibroblasts and human CRC cells. Inhibition of CXCL1 by neutralizing antibody and specific shRNAs decreased CRC 
tumor growth. Highly elevated CXCL1 expression significantly correlated with decreased overall survival in stage IV 
CRC patients (hazard ratio 0.28; 95% CI 0.11–0.72).
Conclusions: High CXCL1 expression is a poor prognostic biomarker in metastatic CRC. CXCL1 inhibition suppressed 
tumorigenic growth of KRAS mutant CRC cells.
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Background
Colorectal rectal cancer (CRC) is the third most com-
monly diagnosed cancer globally with over 1.2 million 
new occurrences annually [1]. The pathogenesis of CRC 
involves a complex and adaptive tumor microenviron-
ment consisting of malignant epithelia with surrounding 
stromal cells such as myofibroblasts and inflammatory 
cells [2]. Autonomous and sustained mitogenic signaling 
in a nutrient poor environment is a fundamental hallmark 
of cancer [3, 4]. Crosstalk between tumor epithelia and 
stroma has emerged to have active roles in tumorigenic-
ity. Both activated and mutated fibroblasts may induce 
autocrine and paracrine factors that mediate epithelia to 
adenocarcinoma transformation [5, 6]. In a human breast 
cancer model, co-culturing of mesenchymal stem cells 
with breast cancer cells enhances invasiveness through 
increased chemokine signaling [7]. Notably, gene expres-
sion profiles of microdissected human breast cancer 
stroma have high prognostic significance, with angio-
genesis and immune-related gene clusters associated 
with poor and favorable prognoses, respectively [8]. In 
human CRC, myofibroblasts are also implicated in tumor 
invasion [9]. Indeed, an increased presence of α-smooth 
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muscle actin expressing myofibroblasts in resected stage 
II–III CRC was an indicator of higher cancer recurrence 
and poor prognosis [10]. The specific interactions within 
human colon cancer epithelia and stroma that signifi-
cantly impact on overall survival remain unclear.
The principal therapy for metastatic CRC therapy relies 
on direct killing of the tumor with cytotoxic chemother-
apy. Recent gains in overall survival have been achieved 
with extracellular targeting of the tumor and its microenvi-
ronment, namely bevacizumab inhibition of angiogenesis, 
cetuximab or panitumumab inhibition of EGFR signaling 
by EGF family ligands, and regorafenib inhibition of mul-
tiple targets [11–14]. Secreted cytokines, chemokines and 
acute phase reactants in the tumor microenvironment 
represent attractive and readily targetable biomarkers if 
they are major drivers of tumor progression in humans 
[15]. To increase our understanding of therapeutically 
relevant secreted factors within the human CRC tumor 
microenvironment, we surveyed the conditioned media of 
human CRC epithelial cells and myofibroblasts for tumo-
rigenic factors that remain elevated under serum nutrient 
deprivation. As these tumorigenic factors may promote 
tumor survival, we determined the extent that their in vivo 
expression levels in human primary CRC tissues impact 
overall survival. We have identified CXCL1 as a constitu-
tively expressed tumorigenic factor whose excess produc-
tion is associated with a significant decrease in overall 
survival of stage IV CRC patients.
Methods
Human mucosal tissues
Human tissues were collected prospectively under an 
IRB approved protocol from patients undergoing elec-
tive surgery for CRC at Memorial Sloan-Kettering 
Cancer Center from January 1990 to December 2000. 
Tissues included normal colon, normal liver, colorectal 
adenomas, primary CRC, and liver and lung metastases 
from primary CRC. Mucosal tissues were pathologically 
verified and obtained by manual microdissection under 
microscopic visualization to remove adjacent connective 
tissue and muscle.
Cells and reagents
Murine NIH3T3 (wildtype KRAS) and human CRC 
cells SW48 (wildtype KRAS) and SW620 (mutant 
KRAS) were obtained from American Type Culture 
Collection (ATCC; Manassas, VA, USA). Human CRC 
myofibroblasts cells (CRC-MF) were isolated from a pri-
mary human colorectal liver metastasis under an IRB 
approved protocol and expressed α-smooth muscle actin. 
All cells were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM) from Invitrogen (Carlsbad, CA, USA) 
supplemented with 10% fetal bovine serum and penicil-
lin, and streptomycin. Antibodies were obtained from 
R&D Systems (goat anti-human CXCL1 antibody, anti-
human IL8 antibody, and control isotypic IgG antibody), 
Invitrogen (donkey anti-goat IgG-Alexa Fluor® 568 conju-
gate antibody) and Sigma (mouse anti-α-smooth muscle 
actin-FITC clone 1A4 antibody).
Generation of lentiviruses
EGFP and neomycin resistant genes were cloned 
into pCCL-PGK lentivirus vector (pCCL-PGK-GFP). 
KRAS12V ORF was amplified by PCR from pcDNA3.1+ 
neo-Kras12V using forward primer 5′-GGG GGA TCC 
ACC GCC ATG ACT GAA TAT AAA CTT GTG-3′ 
and reverse primer 5′-GATT GTC GAC TTA CAT AAT 
TAC ACA CTT TGT CTT TGA C-3′ and cloned into 
the 5′BamHI and 3′SalI sites of pCCL-PGK (pCCL-PGK-
KRAS12V). CXCL1 and non-target control lentiviral 
shRNA TRC1 vectors were obtained from Sigma-Aldrich. 
Lentiviruses were generated by cotransfecting 15  µg of 
lentiviral vector (pCCL-PGK-GFP or -Kras12V), 3.5 µg of 
pENV/VSV-G, 6 µg of pRRE, and 3 µg of pRSV-REV into 
293T cells in 10 cm plates using the calcium precipitation 
method. Lentiviral supernatants were collected at 40 and 
64 h after transfection. Cells were transduced with lenti-
viruses at MOI = 10 and maintained in DMEM growth 
medium.
Conditioned media
Sixteen millions cells of SW620 and CRC-MF were cul-
tured in 20  ml of DMEM supplemented with 10% fetal 
bovine serum. On day 3, the supernatants were col-
lected and the adherent cells were washed twice with PBS 
and maintained in serum-free DMEM for an additional 
3  days. Conditioned media were collected from day 3 
serum+ supernatants and day 6 serum-free supernatants, 
centrifuged for 10 min at 400 g to remove cellular debris, 
sterile filtered through 0.22 µm Millipore filter (Billerica, 
MA, USA), and stored at −80°C prior to use.
Soft agar growth assay
Ten thousand NIH3T3 cells and one thousand SW620 
cells were grown in a 0.33% top layer and a 0.5% bottom 
layer that included Difco Bacto Agar (w/v). The top layer 
contained growth media or conditioned media and the 
bottom layer contained only growth media. On day 14, 
colonies greater than 50 cells were counted visually using 
a stereo zoom microscope. Neutralizing anti-human 
CXCL1 monoclonal antibody, anti-human IL8 mono-
clonal antibody, and control isotypic antibody (R&D 
Systems) at 625 ng/ml of total volume were added at the 
initiation of soft agar assays.
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Murine xenograft tumor assay
Four million human colon cancer cells were injected into 
the dorsal subcutaneous flank of Foxn1nu/Foxn1nu nude 
mice. Growth of tumor xenografts were measured with a 
caliber at the indicated time. All mouse experiments were 
done in compliance with the Institutional Animal Care 
and Use Committee (IACUC) policies.
Elisa
Conditioned media were evaluated for the relative pres-
ence of 57 different cytokines, chemokines, and acute 
phase reactants using the Human Cytokine Array Kit, 
Panel A and Human Chemokine Array from R&D Sys-
tems (Minneapolis, MN, USA) according to manufac-
turer’s instructions. These included CCL1/I-309, CCL2/
MCP-1, CCL3/MIP-1a, CCL4/MIP-1b, CCL5/RANTES, 
CCL7/MCP-3, CCL14/HCC-1/HCC-3, CCL15/MIP-1d/
LKN-1, CCL17/TARC, CCL18/PARC, CCL19/MIP-3b, 
CCL20/MIP-3a, CCL21/6Ckine, CCL22/MDC, CCL26/
Eotaxin-3, CCL28, Chemerin, C5a, CD40 ligand, G-CSF, 
GM-CSF, CXCL1/GRO alpha, CX3CL1/Fractalkine, 
CXCL4/PF4, CXCL5/ENA-78, CXCL7/NAP-2, CXCL8/
IL-8, CXCL9/MIG, CXCL10/IP-10, CXCL11/I-TAC, 
CXCL12/SDF-1, CXCL16, CXCL17/VCC-1, ICAM1, 
IFNg, IL1a, IL1b, IL1RN, IL2, IL4, IL5, IL6, IL10, IL12, 
IL13, IL16, IL17, IL17E, IL23, IL27, IL32 alpha, Lympho-
tactin/XCL1, Midkine, MIF, Serpin E1, TNF-alpha and 
TREM1. Signal intensities were determined from meas-
uring pixel intensity (PI) of scanned images and quanti-
fied with Adobe Photoshop (San Jose, CA, USA). Briefly, 
conditioned media were diluted, mixed with a cocktail of 
biotinylated detection antibodies and incubated with the 
cognate immobilized capture antibody on the cytokine 
array membrane. Streptavidin-horseradish peroxidase 
and chemiluminescent detection reagents were added 
and a signal was produced in proportion to the amount 
of cytokine bound. The cytokine array membranes were 
scanned as TIF images and the signal minus background 
were quantified as pixel intensities (PI).
Quantitative levels of CXCL1 and IL8 in the condi-
tioned media were measured using CXCL1 and IL8 
Quantikine Assay kits (R&D Systems) according to man-
ufacturer’s instructions. The measured optical densities 
of CXCL1 and IL8 in conditioned media were converted 
to concentrations (ng/ml) by linear regression analysis of 
optical densities and standard concentrations of recom-
binant CXCL1 and IL8 proteins.
Immunofluorescence
Formalin fixed paraffin embedded human CRC were sec-
tioned at 4 µm. CRC tissue paraffin slides were warmed 
for 30  min at 60°, deparaffinized in xylenes and graded 
alcohols, treated with antigen retrieval buffer (DAKO) in 
a steamer for 30 min, washed in PBS and blocked for 1 h 
at room temperature with 10% Normal Donkey Serum 
and 0.02% Tween-20 in PBS. Primary goat anti-human 
CXCL1 antibody and mouse anti-α-smooth muscle 
actin-FITC clone 1A4 antibody were incubated overnight 
at 4° and washed away with PBS prior to incubation for 
1  h at room temperature with secondary donkey anti-
goat IgG-Alexa Fluor® 568 conjugate antibody. Labeled 
tissues were sealed with glass covers with Cytoseal and 
immunofluorescence images were collected with Zeiss 
LSM 780 confocal microscopy.
Expression profile of human mucosal tissues
Total RNA was purified with Qiagen RNeasy purifica-
tion column and reagents (Invitrogen) from human 
mucosal tissues. After reverse transcription, the cDNA 
was hybridized to Affymetrix Human Genome U133A 
(mucosal tissues) or U133 Plus 2.0 (SW48 cells) Gene-
Chips per manufacture protocol. MAS-3 software was 
used for obtaining raw signal intensity (SI) data from the 
gene chips. CXCL1 and IL8 mRNA expression values >3 
standard deviations above the mean of baseline normal 
control were considered as significantly gained above 
normal.
Statistics
Statistical analyses for mean, standard error of the mean, 
Spearman correlation, Log-rank test for Kaplan–Meier 
survival curves and linear regression analysis for CXCL1 
and IL8 levels, were performed with GraphPad Prism 
v5.0d (San Diego, CA, USA). Statistical significance for 
multi-groups comparison was based ANOVA.
Results
Human colorectal epithelial cells and myofibroblasts 
secrete tumorigenic factors
The presence of dominant active KRAS mutation 
increases the ability of cells to grow under nutrient poor 
conditions and in an anchorage-independent manner, 
which is an in vitro correlate of in vivo tumorigenicity 
[16]. Murine NIH3T3 fiboblasts that expressed ectopic 
dominant active KRAS12V induced a modest 3.5% effi-
ciency in anchorage-independent growth (Figure  1a). 
Unmodified and ectopic GFP expressing human SW48 
CRC cells, which have endogenous KRASWT, had a base-
line 17% soft agar growth efficiency that increased to 50% 
with ectopic KRAS12V expression (Figure  1a). We have 
confirmed that human SW620 CRC cells, which have 
endogenous KRAS12V, were highly tumorigenic at 56% 
soft agar growth efficiency [16]. Under serum deprivation 
stress, SW620 cells secreted soluble factors into serum-
free conditioned media that significantly enhanced 
soft agar growth of NIH3T3-KRAS12V fibroblast in 
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Figure 1 Conditioned media of human CRC epithelial cells and CRC myofibroblasts induced anchorage‑independent growth. a Percent efficiency 
of anchorage independent growth in soft agar assays of murine NIH3T3 cells that overexpressed GFP or KRAS12V by lentiviral transduction, and 
SW48 and SW620 cells. b Increased anchorage independent growth of malignant NIH3T3‑KRAS12V cells with addition of conditioned‑media from 
SW620 cells that were cultured under stressed serum‑free versus normal serum containing media or control growth media alone. c Serum‑free 
and serum containing conditioned media from SW620 and CRC MF cells maximally induced anchorage independent growth of non‑transformed 
NIH3T3 cells, respectively. d Relative cytokines levels in SW620 and CRC‑MF condition media in the presence and absence of serum. e Secreted 
CXCL1 and IL8 levels in SW620 and CRC‑MF conditioned media in the presence and absence of serum as measured by ELISA. Representative experi‑
ments were shown from n ≥3 experiments. P values were as indicated: *p < 0.05, **p < 0.01, ***p < 0.001.
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comparison to serum DMEM media control or serum 
containing conditioned media (Figure  1b). NIH3T3-
GFP fibroblasts acquired greater anchorage-independent 
growth when exposed to SW620 serum-free compared 
to serum containing conditioned media (Figure  1c). To 
assess non-epithelial sources of secreted tumorigenic 
autocrine and paracrine factors in the tumor microenvi-
ronment, we examined CRC myofibroblasts (CRC-MF). 
In contrast to the effect seen with SW620 conditioned 
media, serum deprivation significantly decreased the 
tumorigenic potential of CRC-MF conditioned media on 
NIH3T3 fibroblasts (Figure 1c). Both human CRC epithe-
lial cells and myofibroblasts secreted tumorigenic factors 
capable of inducing and enhancing anchorage-independ-
ent growth of normal and malignant NIH3T3 fibroblasts.
To identify specific tumorigenic factors present in 
SW620 and CRC-MF conditioned media, we screened 
for the relative presence of 57 cytokines, including 
chemokines and acute phase reactants, in the presence 
and absence of serum. Consistent with their potential 
involvement in promoting tumorigenicity of untrans-
formed NIH3T3 and NIH3T3-KRAS12V cells, only 
CXCL1 and IL8 levels were higher in SW620 serum-free 
versus serum containing conditioned media, and vice 
versa for CRC-MF cells (Figure  1d). Although ectopic 
CXCR2 expression was reported to induce NIH3T3 
malignant transformation in soft agar assay [17], we 
detected high CXCL1 mRNA expression and very low 
CXCR2 mRNA expression in NIH3T3 cells (Addi-
tional file 1: Figure S1A). In comparison to SW620 con-
ditioned media, SW48 conditioned media contained 
greatly reduced level of all cytokines and did not pro-
mote NIH3T3 soft agar growth (Figure 1d and data not 
shown). Quantitative ELISA measurement of secreted 
CXCL1 and IL8 levels in SW620 and CRC-MF condi-
tioned media confirmed their maximal concentrations in 
the serum-free and serum containing conditioned media, 
respectively (Figure 1e).
Elevated CXCL1 decreases overall survival in stage IV CRC
To determine the clinical relevance of elevated CXCL1 
and IL8 levels as potential in vivo drivers of human CRC 
development and prognosis, we compared their RNA 
expression levels to overall survival. To balance out the 
impact of tumor and patient care heterogeneity, we ana-
lyzed human colorectal tissues from patients who were 
treated at a single high volume cancer center from 1991 
to 2000 (Table  1). All primary stage I–IV human CRC 
tissues were pathologically verified. Whereas normal 
human tissues uniformly showed low baseline CXCL1 
and IL8 levels, these levels were greater than three stand-
ard deviations above normal in most human colorectal 
adenoma, adenocarcinoma and metastases to the liver 
and lung (Figure 2a, b; Additional file 2: Table S1). Nota-
bly, elevated CXCL1 levels occurred early in 77% of colon 
adenomas and were sustained at high levels throughout 
81–94% of primary stage I–IV CRC (Figure 2c, e). In con-
trast, elevated IL8 levels occurred only in 19% of colon 
adenomas before increasing in 57–60% of primary stage 
I–IV CRC (Figure 2d, f ). Elevated levels of both CXCL1 
and IL8 were observed in 45–56% of distant colon metas-
tases to the liver and lung. There was a low inverse cor-
relation between TNM stages and the mRNA levels of 
CXCL1 (Spearman r = −0.29; p = 0.0002) but not those 
of IL8 (Spearman r = 0.015; p = 0.85) (Additional file 1: 
Figure S1B and C).
To assess the prognostic significance of elevated 
CXCL1 and IL8, we performed Kaplan–Meier esti-
mates of overall survival in human CRC patients. Stage 
IV patients with highly elevated CXCL1 levels showed 
a significant decrease in median overall survival of 
10.9  months when compared to 23.2  months in those 
with normal baseline expression (Figure  3a). However, 
highly elevated IL8 levels in these stage IV patients did 
not have significant prognostic impact (Figure  3b). In 
our cohort of 88 stage II–III CRC patients, there was no 
significant overall survival difference observed between 
normal and elevated expression levels of CXCL1 and 
IL8 (Figure 3c, d). Subgroup analyses of overall survival 
that excluded rectal cancer patients and included only 
colon cancer patients, which accounted for 85% of total 
Table 1 Baseline characteristics of patients
Characteristics Adenoma Stage I Stage II Stage III Stage IV
Sex (%)
 Male 53 48 53 54 57
 Female 47 52 48 46 43
Age (years)
 Median 68 68 69 66 62
 Range 33–80 35–87 40–84 23–84 19–85
Tumor stage
 T status (%)
  T1 or 2 0 100 0 19 4
  T3 0 0 100 75 83
  T4 0 0 0 4 13
 Nodal status 
(%)
0
  N0 0 0 0 0 30
  N1 0 0 0 56 31
  N2 0 0 0 44 39
  Metastasis (%) 0 0 0 0 100
Type of cancer (%)
 Colon 62 68 88 81 85
 Rectal 38 32 12 19 15
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Figure 2 Overexpression of CXCL1 and IL8 mRNA levels in human CRC development. a, b Box plots of CXCL1 (a) and IL8 (b) mRNA expressions 
in human mucosal tissues of normal colon (NC), normal liver (NL), colon adenoma (A), stages I‑IV primary colorectal adenocarcinoma (I‑IV), and 
CRC metastases to liver (Li) and lung (Lu). c Box plots of CXCL1 mRNA expressions in human primary CRC stratified according to TNM stages. d Box 
plots of IL8 mRNA expressions in human primary CRC stratified according to TNM stages. e Percentages of human colorectal malignant tissues 
with elevated CXCL1 mRNA expression occurred early in most human adenoma (A) and decreased slightly with cancer metastasis. f Percentages of 
human colorectal malignant tissues with elevated IL8 mRNA expression occurred predominantly at time of conversion from adenoma to stage I–II 
CRC and remained elevated with disease progression. “−” and “+” indicated normal mRNA levels and those that were three standard deviations 
above normal, respectively. SI represented arbitrary unit of signal intensity. Patient numbers (n) were as indicated.
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patients, showed similar overall survival differences 
(Additional file 3: Figure S2). Overall, these data indicate 
that CXCL1 overexpression is a poor prognostic bio-
marker in metastatic CRC.
Lowering CXCL1 level decreased tumorigenic growth
As elevated CXCL1 level corresponded with increased 
tumorigenicity induced by conditioned media and poor 
prognosis in stage IV CRC, we investigated the biologic 
and therapeutic effects of its suppression. The addition of 
neutralizing anti-CXCL1 antibody to SW620 and CRC-
MF derived conditioned media partially inhibited their 
ability to induce soft agar growth of murine NIH3T3 
fibroblasts (Figure  4a). Similarly, soft agar growth of 
highly tumorigenic SW620 cells was inhibited in the 
presence of neutralizing anti-CXCL1 antibody but not 
IgG control antibody (Figure  4b). We next generated 
SW620 cells that stably secreted greatly reduced CXCL1 
levels in the conditioned media, as confirmed by ELISA, 
using two different lentiviral shRNAs targeting CXCL1 
gene expression versus non-target shRNA control (Fig-
ure 4c). SW620 cells with specific reduction of secreted 
CXCL1 levels showed 85% and 79% reduction in soft agar 
colony growth (Figure 4d).
To test whether CXCL1 levels correlated with in vivo 
tumorigenicity, we performed murine tumor xenograft 
assay. In comparison to those of the non-target shRNA 
control, the mean tumor volumes of SW620 cells were 
decreased by 71% and 73% in the presence of two dis-
tinct CXCL1 shRNAs (Figure  5a). We previously dem-
onstrated CXCL1 protein expression in human CRC 




































































































Figure 3 Highly elevated levels of CXCL1, but not IL8, associated with poor prognosis in stage IV human CRC. a–d Kaplan–Meier estimates of 
overall survival in stages IV (a, b) and II‑III (c, d) CRC patients that were stratified according to normal (gray line; +/−), and upper‑quartile (color line; 
++) ranges of CXCL1 (a, c) or IL8 (b, d) levels. The patient numbers at risk (n) were as indicated for the groups.
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the human CRC tumor microenvironment by immuno-
fluorescence revealed co-localization of CXCL1 protein 
expression with tumor myofibroblasts, which expressed 
α-smooth muscle actin (Figure  5b). Furthermore, we 
observed in primary human stage I–IV CRC a moder-
ate correlation between CXCL1 mRNA levels and its 
specific CXCR2 receptor, but not CXCR1, a related 
chemokine receptor that does not bind CXCL1 (Fig-
ure 5c, d). We conclude that human CRC epithelia and 
myofibroblasts secrete elevated CXCL1 to promote in 
vivo tumorigenic growth.
Discussion
While human CRC is known to involve numerous tumo-
rigenic factors, the specific therapeutically relevant fac-
tors that significantly impact overall survival remains 
poorly characterized. Here, we have identified consti-
tutively elevated levels of CXCL1 as a bona fide driver 
of human CRC development and poor overall survival 
in stage IV CRC patients. We have elucidated a com-
plementary adaptive response to serum deprivation by 
human CRC epithelial cells and myofibroblasts, thereby 
maintaining high tumorigenic CXCL1 level in the tumor 
microenvironment throughout the adenoma-adenocarci-
noma sequence. These findings provide new insights that 
indentify CXCL1 as a key targetable biomarker whose 
inhibition may increase overall survival in CRC patients.
Dominant active KRAS mutation is the main onco-
genic driver in approximately half of sporadic metastatic 
colorectal adenocarcinoma [19]. In comparison to KRAS 
wildtype SW48 CRC epithelial cells, the KRAS mutant 
SW620 CRC cells used in our study demonstrated high 
efficiency in tumorigenic growth and secreted higher 
level of inflammatory chemokines such as CXCL1 and 
IL8. In comparison to wildtype RAS, mutant RAS also 
induced greater inflammatory cytokines in breast, 
lung, and pancreatic cancer cells [20–22]. The levels 
of CXCL1 and IL8 secreted are consistent with those 
of other human colorectal and gastric cancer cell lines 
[23]. We now show that the CXCL1 secreted in SW620 
conditioned media are capable of inducing tumorigenic 
growth. Our observations that decrease CXCL1 secretion 
by SW620 cells inhibited their anchorage-independent 
and xenograft tumor growth are supported by simi-
lar findings in KRAS mutant LS174T CRC cells, whose 
malignant growth were inhibited by CXCL1 siRNA or 
neutralizing α-CXCL1 antibody [24, 25]. Treatment 
of KRAS mutant DLD-1 CRC cells with KRAS siRNA 
resulted in suppression of KRAS mutant expression and 
a corresponding decrease in CXCL1 level [26]. Interest-
ingly, colorectal tumors that developed due to chronic 
ulcerative colitis had a lower frequency of KRAS muta-
tion [27]. The decrease involvement of mutant KRAS 
in this setting may be explained by the inherently high 
CXCL1 expression driven by the underlying inflamma-
tory disease [28]. Together these data suggest mutant 
KRAS increases inflammatory cytokines, in particular 
CXCL1, as a way to enhance sporadic CRC development.
Malignant tumors survive and thrive due to their great 
versatility in overcoming environmental limitations. 
Within the human CRC microenvironment, malignant 
epithelia and myofibroblasts drive tumor progression. 
Striking differences exist between the relative cellular 
sources of CXCL1 and IL8 secreted by epithelial cells and 
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Figure 4 Induction of anchorage‑independent growth by SW620 
and CRC‑MF conditioned media was dependent on CXCL1. a Neutral‑
izing antibodies to CXCL1, in comparison to irrelevant isotype‑specific 
control IgG Ab, inhibited the anchorage independent growth of non‑
transformed NIH3T3 cells induced by serum‑free SW620 and serum‑
containing CRC‑MF conditioned media. b Neutralizing antibodies to 
CXCL1 inhibited the anchorage independent growth of malignant 
SW620 cells in comparison to irrelevant isotype‑specific control IgG 
Ab. c, d SW620 cells stably expressing two different CXCL1 specific 
shRNAs secreted lower CXCL1 levels (c) and had suppressed soft 
agar growth (d) in comparison to control shRNA. p values were as 
indicated: *p < 0.05, **p < 0.01, ***p < 0.001.
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under serum enriched and deprived conditions. Con-
sistent with their tumorigenic induction and promo-
tion of anchorage independent growth of NIH3T3 and 
NIH3T3-KRAS12V cells, there was a reciprocal increase 
and decrease in secreted CXCL1 and IL8 levels by SW620 
and CRC-MF cells as a result of serum deprivation. Under 
optimal conditions, human CRC myofibroblasts secreted 
CXCL1 and IL8 at 50 and 80 fold higher levels, respec-
tively, than human CRC epithelial cells when quantified 
on a per cell basis. In addition to the prominent malignant 
epithelia, the human CRC microenvironment had a mean 
stromal myofibroblasts abundance of 6% (0.4–19%) and 
9% (2–24%) when assessed by α-smooth muscle actin 
and vimentin expressions, respectively [10, 29]. Based on 
mean α-smooth muscle actin expression of 6%, myofibro-
blasts secreted approximately threefold (range 0.2–11.7) 
more CXCL1 and fivefold (range 1.6–19 fold) more IL8 
in comparison to malignant epithelia. This suggests that 
secreted CXCL1 and IL8 are derived from myofibro-
































































Figure 5 CXCL1 contributed to in vivo human CRC tumor growth. a SW620 cells stably expressing two distinct CXCL1 specific shRNAs had sup‑
pressed xenograft tumor growth in immunocompromised mice (n = 4 per group) with tumor images at right. b Immunofluorescence of human 
CRC detected CXCL1 protein expression (red) in CRC epithelia (asterisks) and co‑localization with tumor myofibroblasts (arrowheads), which 
expressed α‑smooth muscle actin (green). c, d In primary stage I–IV human CRC, mRNA levels of CXCL1 show a moderate correlation with CXCR2 
(Spearman r = 0.34; CI 0.20–0.48) but not CXCR1 (Spearman r = −0.04; 95% CI −0.20 to 0.11).
Page 10 of 12le Rolle et al. J Transl Med  (2015) 13:199 
human colon cancer epithelia under serum nutrient dep-
rivation. Our finding that CXCL1 was also expressed by 
CRC myofibroblasts is consistent with its detection in 
the stroma of colonic tumor tissue microarrays [30]. In 
multivariate analysis of stage II–III human colon cancer 
patients, high expression of α-smooth muscle actin and 
vimentin but not stromal collagen, led to increase disease 
recurrence and decrease overall survival [10, 29]. Notably, 
a gene expression profile of human breast cancer tumor 
stroma that was associated with poor prognosis also 
showed elevated CXCL1, although the specific cell source 
for this secreted CXCL1 factor is difficult to determine 
in vivo due to potential cross contamination from breast 
cancer epithelia and stromal cells [8].
We extend our in vitro human cell experiments with 
in vivo human colorectal tissue analyses. We and others 
have reported that elevated levels of CXCL1 or IL8 in 
human colon cancer cells promotes tumorigenicity and 
are upregulated in human ulcerative colitis and colon 
cancer [18, 31–34]. We observe that elevated CXCL1 
mRNA expression in human occurs throughout the 
adenoma-adenocarcinoma sequence with early induc-
tion in 77% of adenomas. In contrast, elevated IL8 RNA 
expression mainly occurs upon transition to stage I colo-
rectal adenocarcinoma and is absent in 81% of adenomas, 
which is consistent with another other study [35, 36]. 
Our analyses showing CXCL1 overexpression in most 
colorectal adenomas and its low inverse correlation with 
TNM stages suggest that CXCL1 has important roles in 
both CRC initiation and tumor progression. The angio-
genic and inflammatory function of CXCL1 in colorectal 
adenoma may contribute to new blood vessel formation 
and the recruitment of important supporting stromal and 
inflammatory cells that are critical to tumor initiation of 
tumor growth. We determine that the levels of CXCL1 
and IL8 did not significantly affect overall survival in 
stage II and III human colon cancer, a finding supported 
by another group [37]. We also observed a significant and 
substantial overall survival difference in stage IV CRC 
that is inversely related to high expression of CXCL1 
but not IL8. The lack of overall survival difference based 
on IL8 levels in our stage-stratified CRC patients is in 
contrast to a prior report that showed higher IL8 level 
led to decrease overall survival in non-stratified stage 
I–IV colon cancer patients [35, 36]. There are conflict-
ing reports as to whether IL8 levels are associated with 
colorectal progression and stage [36, 37]. As both CXCL1 
and IL8 are inflammatory chemokines, this suggests that 
the poor overall survival difference observed may be spe-
cific to CXCL1 dependent effect instead of a generalized 
inflammatory response.
The overall survival analysis of CXCL1 and IL8 in our 
study relies on comparing mRNA expression levels in 
human colorectal mucosal tissues to patient outcome. It 
is well established that both CXCL1 and IL8 production 
are regulated mainly at the transcriptional level by nuclear 
factor-κB and other transcriptional regulators [38–40]. We, 
along with other investigators, have validated in human 
colon benign and malignant tissues that CXCL1 and IL8 
mRNA levels correlated with RT-PCR quantification and 
protein expression by immunohistochemistry [18, 34, 
36, 41]. The strengths of our survival analysis in primary 
CRC patients included our stratification for TNM stages 
and pathologic confirmation of predominantly malignant 
tissues of moderately differentiated histology from a high 
volume cancer center where overall survival is better than 
expected with standard of care therapy. Tumor stage is the 
best prospectively validated prognostic indicator of overall 
survival in colon cancer, and tumor stage stratification is a 
prerequisite for prognostic biomarker analysis.
Our observation that a highly elevated level of CXCL1 
is associated significantly with decreased overall survival 
offers an accessible extracellular target for therapeutic 
intervention. CXCL1 acts primarily through its recep-
tor CXCR2. We have reported previously that the mean 
expression of CXCR2 was decreased in dissected mucosal 
tissues of human colon adenoma, primary colon adeno-
carcinoma and metastasis [18]. The reduction of CXCR2 
level alleviates both replicative and oncogene-induced 
senescence and thereby promotes tumorigenesis, and in 
cells in that have compromised senescence machinery, 
such as p53 null mouse embryonic fibroblasts or NIH3T3 
cells, autocrine CXCR2 signaling becomes pro-oncogenic 
[42]. We have observed a significant moderate correlation 
between levels of CXCL1 and CXCR2, suggesting that 
in CRC patients with high CXCL1, the CXCR2 receptor 
was also elevated. In a preclinical human colon cancer cell 
growth and metastasis model in nude mice, orally active 
CXCR2/CXCR1 antagonists partially decreased liver 
metastasis by reducing tumor neovascularization through 
CXCR2 signaling [43]. More effective tumor suppression 
may be achieved with dual CXCL1 and CXCR2 blockage.
In our study of stage IV CRC, the 12.5 months improve-
ment in median overall survival between CXCL1 levels in 
the normal versus upper quartile range greatly exceeds 
the median overall survival improvement of 4.7 months 
for additional bevacizumab therapy and 3.5  months for 
cetuximab therapy [11, 12]. In summary, direct inhibitory 
targeting of CXCL1 signaling represents a very promising 
avenue toward overall survival benefit in human CRC.
Conclusions
Our study suggests that highly elevated CXCL1 expres-
sion promotes tumorigenicity and serves as a poor prog-
nostic biomarker in metastatic CRC patients. CXCL1 
inhibition suppresses CRC tumor growth and warrants 
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further investigation as a candidate therapeutic target in 
metastatic colorectal cancer.
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